Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dadiomov

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Managed Care & Specialty Pharmacy|December 28, 2019
Dissociating the Clinical Role and Economic Value of Intranasal EsketamineDavid Dadiomov
The Mental Health Clinician|January 11, 2019
The effects of ketamine on suicidality across various formulations and study settingsDavid Dadiomov, Kelly Lee
The Mental Health Clinician|April 14, 2025
Community pharmacy attitudes and behaviors following a buprenorphine best practices disseminationWinter Roth, David Dadiomov
Therapeutic Advances in Drug Safety|December 11, 2023
Inappropriate quetiapine use at a large academic medical center: frequency of misuse and associated costs of adverse effectsWinter Roth, David Dadiomov, Michelle Chu
Journal of the American Pharmacists Association : Japha|November 28, 2022
Lowering barriers to naloxone access through a student-led harm reduction programMari Brown, Christopher Tran, David Dadiomov
The American Journal of Hospice & Palliative Care|August 2, 2018
Using the LACE Score as a Predictor of Clinical Outcomes in Patients Referred for Inpatient Palliative Care Consultation: A Single-Center ExperienceDavid Dadiomov, Patricia Keefer, Michael A Smith
Pharmaceuticals (Basel, Switzerland)|July 17, 2020
Safety of Repeated Administration of Parenteral Ketamine for DepressionDavid Feifel, David Dadiomov, Kelly C Lee
Harm Reduction Journal|June 29, 2022
Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemicDavid Dadiomov, Maria Bolshakova, Melania Mikhaeilyan, et al.
Drug and Alcohol Dependence|January 16, 2022
Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemicDavid Dadiomov, Rebecca Trotzky-Sirr, Andrew Shooshtari, et al.
Npj Mental Health Research|October 5, 2024
Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcomeJack D C Dahan, David Dadiomov, Tijmen Bostoen, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Managed Care & Specialty Pharmacy|December 28, 2019
Dissociating the Clinical Role and Economic Value of Intranasal EsketamineDavid Dadiomov
The Mental Health Clinician|January 11, 2019
The effects of ketamine on suicidality across various formulations and study settingsDavid Dadiomov, Kelly Lee
The Mental Health Clinician|April 14, 2025
Community pharmacy attitudes and behaviors following a buprenorphine best practices disseminationWinter Roth, David Dadiomov
Therapeutic Advances in Drug Safety|December 11, 2023
Inappropriate quetiapine use at a large academic medical center: frequency of misuse and associated costs of adverse effectsWinter Roth, David Dadiomov, Michelle Chu
Journal of the American Pharmacists Association : Japha|November 28, 2022
Lowering barriers to naloxone access through a student-led harm reduction programMari Brown, Christopher Tran, David Dadiomov
The American Journal of Hospice & Palliative Care|August 2, 2018
Using the LACE Score as a Predictor of Clinical Outcomes in Patients Referred for Inpatient Palliative Care Consultation: A Single-Center ExperienceDavid Dadiomov, Patricia Keefer, Michael A Smith
Pharmaceuticals (Basel, Switzerland)|July 17, 2020
Safety of Repeated Administration of Parenteral Ketamine for DepressionDavid Feifel, David Dadiomov, Kelly C Lee
Harm Reduction Journal|June 29, 2022
Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemicDavid Dadiomov, Maria Bolshakova, Melania Mikhaeilyan, et al.
Drug and Alcohol Dependence|January 16, 2022
Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemicDavid Dadiomov, Rebecca Trotzky-Sirr, Andrew Shooshtari, et al.
Npj Mental Health Research|October 5, 2024
Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcomeJack D C Dahan, David Dadiomov, Tijmen Bostoen, et al.
Pageof 2